Jakafi Xr is a drug owned by Incyte Corp. It is protected by 17 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 17, 2034. Details of Jakafi Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | Active |
| US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(1 year, 6 months from now) | Active |
| US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(1 year, 6 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11337927 | Sustained-Release Dosage Forms Of Ruxolitinib |
Jan, 2034
(7 years from now) | Active |
| US11576864 | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | Active |
| US11896717 | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | Active |
| US11576865 | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | Active |
| US10874616 | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | Active |
| US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | Active |
| US11213528 | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | Active |
| US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | Active |
| US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | Active |
| US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(5 months from now) | Active |
| US9206187 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase |
Dec, 2026
(5 months from now) | Active |
| US11744832 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(5 months from now) | Active |
| US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(5 months from now) | Active |
| US8530485 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(5 months from now) | Active |
Several oppositions have been filed on Jakafi Xr's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Jakafi Xr's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Jakafi Xr patents.
Jakafi Xr's Oppositions Filed in EPO
Jakafi Xr has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 21, 2012, by Fresenius Kabi Deutschland Gmbh. This opposition was filed on patent number EP06839328A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16152794A | Sep, 2019 | Generics (UK) Ltd | Revoked |
| EP16197502A | Jun, 2019 | Concert Pharmaceuticals, Inc. | Granted and Under Opposition |
| EP08770794A | Dec, 2014 | Actavis Group PTC ehf | Patent maintained as amended |
| EP08770794A | Dec, 2014 | Generics [UK] Ltd (trading as Mylan) | Patent maintained as amended |
| EP06839328A | Jun, 2012 | Fresenius Kabi Deutschland GmbH | Opposition procedure closed |
US patents provide insights into the exclusivity only within the United States, but
Jakafi Xr is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Jakafi Xr's family patents as well as insights into
ongoing legal events
on those patents.
Jakafi Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Jakafi Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 17, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Jakafi Xr Generics:
There are no approved generic versions for Jakafi Xr as of now.
Alternative Brands for Jakafi Xr
There are several other brand drugs in the same treatment category and using the same active ingredient (Ruxolitinib Phosphate) as Jakafi Xr. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Incyte Corp |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ruxolitinib Phosphate. Given below is the list of those drugs and companies owning them.
About Jakafi Xr
Jakafi Xr is a drug owned by Incyte Corp. Jakafi Xr uses Ruxolitinib Phosphate as an active ingredient. Jakafi Xr was launched by Incyte in 2026.
Approval Date:
Jakafi Xr was approved by FDA for market use on 01 May, 2026.
Active Ingredient:
Jakafi Xr uses Ruxolitinib Phosphate as the active ingredient. Check out other Drugs and Companies using Ruxolitinib Phosphate ingredient
Dosage:
Jakafi Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 11MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 44MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 33MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 22MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 55MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |